CMS Says 'Open Payments' Data Easier To Use, But Some See Reporting Inefficiencies

 
• By Sue Darcey

As CMS releases its 2015 "Open Payments" data on device and drug company payments to physicians, the agency is citing improvements in search tools and usability of the data. But one small startup device firm described onerous and inefficient reporting requirements, and the American Medical Association is citing "registration challenges" and continued data errors on the physician end.

As CMS unleashes its latest data on money or other transfers-of-value that device and drug firms gave physicians, teaching hospitals and clinical researchers, it is touting several enhancements to the Open Payments database. However, some firms and a major physicians group are still citing inefficiencies and other troubles they are running into in reporting their payments to the federally mandated transparency database.

On June 30, CMS published "Open Payments" data

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Ceryx Medical Amasses £11M To Develop Adaptive Cardiac Pacing Technology

 
• By Natasha Barrow

The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.

SS Innovations’ SSI Mantra 3 Poised To Challenge Da Vinci In Robotic Surgery Market

 
• By Marion Webb

SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.